Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61-2-9472-4101
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.12 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions
What is Kazia Therapeutics' stock symbol?
Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."
Has Kazia Therapeutics been receiving favorable news coverage?
News headlines about KZIA stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kazia Therapeutics earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. View News Stories for Kazia Therapeutics.
Who are some of Kazia Therapeutics' key competitors?
Some companies that are related to Kazia Therapeutics include Sunesis Pharmaceuticals (SNSS), Enlivex Therapeutics (ENLV), TFF Pharmaceuticals (TFFP), Vaccinex (VCNX), Immunic (IMUX), Sesen Bio (SESN), Synlogic (SYBX), VERONA PHARMA P/S (VRNA), Oramed Pharmaceuticals (ORMP), CV Sciences (CVSI), Checkpoint Therapeutics (CKPT), AVEO Pharmaceuticals (AVEO), Catalyst Biosciences (CBIO), Neos Therapeutics (NEOS) and Infinity Pharmaceuticals (INFI).
What other stocks do shareholders of Kazia Therapeutics own?
Who are Kazia Therapeutics' key executives?
Kazia Therapeutics' management team includes the folowing people:
- Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
- Ms. Gabrielle Heaton, Director of Fin. & Admin.
- Ms. Catherine Jane Hill, Company Sec. (Age 60)
- Kym Robins, Director of Marketing & Communications
- Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program
How do I buy shares of Kazia Therapeutics?
Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kazia Therapeutics' stock price today?
One share of KZIA stock can currently be purchased for approximately $4.06.
How big of a company is Kazia Therapeutics?
Kazia Therapeutics has a market capitalization of $25.25 million and generates $1.12 million in revenue each year. The company earns $-7,340,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. View Additional Information About Kazia Therapeutics.
What is Kazia Therapeutics' official website?
How can I contact Kazia Therapeutics?
Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at 61-2-9472-4101 or via email at [email protected]
MarketBeat Community Rating for Kazia Therapeutics (NASDAQ KZIA)
MarketBeat's community ratings are surveys of what our community members think about Kazia Therapeutics and other stocks. Vote "Outperform" if you believe KZIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZIA will underperform the S&P 500 over the long term. You may vote once every thirty days.
